cetuximab,encorafenib,binimetinib
pfizer,eli lilly,array biopharma
['colorectal', 'biomarker', 'beacon', 'rectal']
findings from the beacon study, led by our dr. scott kopetz, identified mechanisms and potential biomarkers of acquired resistance in colorectal cancer, and could help develop strategies to overcome treatment resistance. read more: #esmo22 #endcancer 
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789